ImmunityBio (NASDAQ:IBRX) Stock Price Down 8.8% on Insider Selling

ImmunityBio, Inc. (NASDAQ:IBRX) shares traded down 8.8% on Wednesday following insider selling activity. The company traded as low as $10.52 and last traded at $10.5330. 32,976,513 shares were traded during trading, a decline of 26% from the average session volume of 44,764,813 shares. The stock had previously closed at $11.55.

Specifically, Director Barry J. Simon sold 10,000 shares of ImmunityBio stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $9.25, for a total value of $92,500.00. Following the completion of the transaction, the director directly owned 3,081,604 shares of the company’s stock, valued at $28,504,837. The trade was a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Barry J. Simon sold 165,000 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the transaction, the director directly owned 2,925,821 shares in the company, valued at $29,989,665.25. This trade represents a 5.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In other news, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a report on Monday. BTIG Research increased their price target on shares of ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Piper Sandler boosted their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Finally, Jefferies Financial Group boosted their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.60.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial traction: Management reported large, broadening regulatory approvals and new commercial partnerships that expand ANKTIVA’s global market opportunity — a key driver of investor enthusiasm. Read More.
• Positive Sentiment: Huge revenue surge driven by ANKTIVA: Company-reported revenue jumped roughly 671–700% year‑over‑year as ANKTIVA adoption scaled, which underpins the view that commercial sales are ramping. Read More.
• Positive Sentiment: Quarterly beat: Q4 EPS loss was smaller than expected and revenue topped consensus (~$38.3M), which analysts and media cited as proof commercial momentum is real. Read More.
• Positive Sentiment: Analyst support and higher long‑term forecasts: Several shops (including D. Boral Capital and HC Wainwright) have reiterated buy ratings and raised medium/long‑term targets, giving the share‑price rally institutional backing. Read More.
• Neutral Sentiment: Corporate visibility: Founder Patrick Soon‑Shiong will speak at high‑profile cancer summits — boosts credibility and attention but not an immediate financial catalyst. Read More.
• Neutral Sentiment: Market commentary about valuation vs. fundamentals: Some analysts and commentators note a disconnect between rapid share gains and the company’s clinical/financial runway; this is shaping debate about how durable the rally is. Read More.
• Negative Sentiment: Insider selling: Directors (Barry Simon and Christobel Selecky) disclosed sales this week totaling large blocks of shares, which can amplify intraday selling pressure after a big run‑up. Read More.
• Negative Sentiment: Near‑term estimate cuts and persistent unprofitability: HC Wainwright trimmed several 2026 quarterly EPS forecasts even while raising long‑term targets, and company remains unprofitable — keeping execution and valuation risks front‑of‑mind. Read More.
• Negative Sentiment: Technical/profit‑taking after a big run: The stock’s rapid move toward a 52‑week high invites profit‑taking and higher intraday volatility; that appears to be driving today’s pullback. Read More.

ImmunityBio Price Performance

The business’s 50-day moving average is $4.82 and its two-hundred day moving average is $3.24. The firm has a market cap of $10.19 billion, a P/E ratio of -27.26 and a beta of 0.14.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. Equities research analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds have recently added to or reduced their stakes in the business. Slow Capital Inc. acquired a new position in shares of ImmunityBio in the third quarter valued at $25,000. Truist Financial Corp bought a new stake in shares of ImmunityBio during the 3rd quarter worth about $27,000. Swiss Life Asset Management Ltd acquired a new position in ImmunityBio in the 3rd quarter valued at about $27,000. WealthPlan Investment Management LLC bought a new position in ImmunityBio in the 4th quarter valued at about $27,000. Finally, Diversify Advisory Services LLC acquired a new stake in ImmunityBio during the second quarter worth approximately $27,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.